Jean‑Yves Blay is one of Europe’s most senior medical oncologists, renowned for his work on sarcomas, gastrointestinal stromal tumours (GISTs) and the broader group of rare adult solid cancers. He serves as President of UNICANCER, the French federation that coordinates the country’s 18 comprehensive cancer centres, and as General Director of the Centre Léon Bérard in Lyon, a leading European cancer centre. Blay also holds a professorship in medical oncology at Université Claude Bernard Lyon 1.
Leadership of EURACAN – Europe’s rare‑cancer network
Since 2017, Blay has directed the European Reference Network for Rare Adult Solid Cancers (EURACAN), a virtual collaboration that brings together more than 100 highly specialised centres in 25 European Union members. The network’s stated mission is “to share expertise and improve access to care for patients across the European Union” and it covers ten disease domains ranging from sarcomas to rare brain tumours euracan.eu. EURACAN’s activities include the development of 22 clinical practice guidelines, multilingual patient information brochures, and a series of training programmes for health‑care professionals.
Rare adult solid cancers affect roughly 500,000 people in Europe each year, accounting for about 24 % of all cancers but responsible for 30 % of cancer‑related deaths ncbi.nlm.nih.gov. By linking national reference centres, EURACAN helps to reduce diagnostic delays, standardise treatment pathways and facilitate cross‑border access to specialised care—a public‑health priority recognized by the European Commission’s ERN framework.
National coordination of sarcoma care
In France, Blay coordinates NETSARC+, the INCa‑certified sarcoma network that unites more than 70 pathology and surgery units nationwide. Centralised pathology review within NETSARC+ has been shown to cut misdiagnosis rates from 30 % to under 10 % and to improve overall survival for sarcoma patients centreleonberard.fr. He also chairs the French Sarcoma Group and contributes to the World Sarcoma Network, reinforcing international collaboration on rare‑tumour research.
Genomic innovation through AURAGEN
Blay is Scientific Director of AURAGEN, France’s high‑throughput whole‑genome sequencing platform launched under the “France Génomique 2025” plan. AURAGEN aims to generate rapid molecular profiles for patients with rare cancers, enabling enrolment in targeted‑therapy trials and supporting precision‑medicine initiatives across the European Union.
Why this matters for patients and health systems
Rare cancers are intrinsically fragmented; more than 300 distinct entities are defined by an incidence under six cases per 100,000 people per year. This fragmentation hampers the generation of robust clinical trial data and leaves many patients without evidence‑based treatment options. Coordinated networks such as EURACAN and NETSARC+ provide a safety net, ensuring that a patient diagnosed with an ultra‑rare sarcoma in a peripheral hospital can be referred to a centre with the requisite expertise, pathology review and access to experimental therapies. From a public‑health perspective, improving outcomes for this sizable minority reduces the overall cancer mortality burden and aligns with the EU’s “Beating Cancer” mission.
Recognition and ongoing influence
In December 2024, Blay was listed among “The 100 Most Influential People in Oncology 2025,” highlighting his impact on clinical practice, research policy and patient advocacy. He previously served as President of the European Organisation for Research and Treatment of Cancer (EORTC) from 2009 to 2012 and acted as Scientific President of the 2019 ESMO Congress, underscoring his long‑standing leadership in European oncology.
What readers should take away
For patients living with a rare adult solid tumour, the existence of coordinated networks means more reliable diagnosis, access to specialised multidisciplinary tumour boards, and eligibility for innovative clinical trials—often across borders. Health‑care providers should be aware of EURACAN’s clinical practice guidelines and the referral pathways offered by national networks such as NETSARC+, as these resources can directly affect treatment decisions and outcomes.
For a deeper look at rare‑cancer policy and clinical guidance, read more on Globally Pulse Health.
